Teodora Brose
Family Medicine · Appomattox, VANPI 1730594029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 735 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,917 and has fallen 96.9% since, to $89 in 2025. Among family medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 735 payments — averaging $12.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$955
- Johnson & Johnson$922
- Pfizer$729
- Lilly USA, LLC$628
- plus $4K from 29 others
Across 174 payments — averaging $614.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$88K
- Novartis$19K
What the payments were for
- Food & beverage$9,530100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $1,349 |
| AbbVie(2 entities) | 122 | $1,312 |
| AstraZeneca | 45 | $955 |
| Johnson & Johnson | 74 | $922 |
| Pfizer | 79 | $729 |
| Lilly USA, LLC | 41 | $628 |
| Amgen | 38 | $535 |
| Biohaven Pharmaceutical Holding Company Ltd. | 45 | $360 |
| Biohaven Pharmaceuticals, Inc. | 22 | $351 |
| Abbott | 15 | $307 |
| GSK | 21 | $291 |
| Boehringer Ingelheim | 19 | $260 |
| Esperion Therapeutics, Inc. | 13 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $210 |
| Amarin Pharma, Inc. | 8 | $144 |
| Merck | 7 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $99 |
| Nestle Healthcare Nutrition Inc. | 5 | $82 |
| Astellas Pharma US Inc | 5 | $78 |
| Genentech USA, Inc. | 5 | $74 |
| Sanofi-aventis U.S. LLC | 5 | $70 |
| Dexcom, Inc. | 5 | $69 |
| Novartis | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Arbor Pharmaceuticals, Inc. | 2 | $50 |
| Sanofi Pasteur Inc. | 3 | $39 |
| Bayer | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$317
- BREZTRI$110
- SYMBICORT$101
- BREZTRI AEROSPHERE$101
How this compares
$9,551 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $257,764 |
| MounjaroTirzepatide | 78 | $93,395 |
| JanuviaSitagliptin Phosphate | 63 | $80,075 |
| EliquisApixaban | 79 | $77,147 |
| TrulicityDulaglutide | 63 | $69,541 |
| FarxigaDapagliflozin Propanediol | 64 | $59,828 |
| CreonLipase/Protease/Amylase | 25 | $59,413 |
| JardianceEmpagliflozin | 52 | $58,898 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $42,727 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $23,834 |
| XareltoRivaroxaban | 20 | $22,197 |
| InvokanaCanagliflozin | 12 | $20,780 |
| LinzessLinaclotide | 24 | $20,124 |
| MyrbetriqMirabegron | 18 | $12,785 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $11,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,349 | $257,764195 claims |
| Lilly USA, LLCMounjaro, Trulicity | $628 | $162,936141 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Crestor, Nexium | $955 | $118,035150 claims |
| MerckJanuvia | $107 | $80,07563 claims |
| AbbVieCreon, Linzess | $1,312 | $79,53749 claims |
| PfizerEliquis | $729 | $77,14779 claims |
| Boehringer IngelheimJardiance | $260 | $58,89852 claims |
| Johnson & JohnsonXarelto, Invokana | $922 | $42,97732 claims |
| GSKTrelegy Ellipta | $291 | $23,83414 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $78 | $18,87429 claims |
| Sanofi-aventis U.S. LLCLantus | $70 | $4,35915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Appomattox
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.